ReviewReviews in endocrine & metabolic disorders2020
Endocrine and metabolic aspects of the COVID-19 pandemic.
Review in Reviews in endocrine & metabolic disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hypophysitis in COVID-19: a systematic review.Pituitary · 2024Pooled it
- Review
- Testosterone protects from metabolic syndrome-associated lung dysfunction in a high-fat diet rabbit model.Endocrinology · 2026Article
- Disrupted fluid homeostasis in patients with post-Covid-19 syndrome - a case series.Frontiers in endocrinology · 2026Article
- Association Between COVID-19 Infection and Thyroid Cancer Development: A Retrospective Cohort Study Using the TriNetX Database.Biomedicines · 2025Article
- Effect of obesity on the acute response to SARS-CoV-2 infection and development of post-acute sequelae of COVID-19 (PASC) in nonhuman primates.PLoS pathogens · 2025Article
- Progress in research on osteoporosis secondary to SARS-CoV-2 infection.Animal models and experimental medicine · 2025Review
- A case of central diabetes insipidus after COVID-19 as a probable diagnosis of lymphocytic infundibulo-neurohypophysitis with positive anti-rabphilin-3A antibodies with review of literature.Endocrine journal · 2024Review
- [Metabolic alterations observed in patients undergoing endocrinological follow-up during the first year of confinement due to Covid-19]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2024Observational
- Hypocalcemia Following Thyroidectomy in a Patient With COVID-19: A Case Report and Literature Review.Cureus · 2024Article
- Review
- Research progress of post-acute sequelae after SARS-CoV-2 infection.Cell death & disease · 2024Review
- Case report: Neglected subacute thyroiditis: a case following COVID-19 vaccination.Frontiers in medicine · 2024Article
- SARS-CoV-2 Affects Thyroid and Adrenal Glands: AnBiomedicines · 2023Article
- Neurogenic diabetes insipidus in a critical patient with COVID-19 pneumonia in treatment with extracorporeal membrane oxygenation: a case report.The journal of extra-corporeal technology · 2023Article
- Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study.Journal of clinical medicine · 2023Article
- Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization.Endocrine · 2023Article
- Association between Hypocalcemia and Outcome in COVID-19 Patients: A Retrospective Study.Journal of laboratory physicians · 2023Article
- Exploring disparities and novel insights into metabolic and cardiovascular comorbidities among COVID-19 patients in Mexico.Frontiers in public health · 2023Observational
- The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury.Frontiers in cardiovascular medicine · 2023Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 infection has tremendously impacted our daily clinical practice as well as our social living organization. Virtually all organs and biological systems suffer from this new coronavirus infection, either because the virus targets directly specific tissues or because of indirect effects. Endocrine diseases are not an exception and some of endocrine organs are at risk of direct or indirect lesion by COVID-19. Although there is still no evidence of higher predisposition to contract the infection in patients with diabetes and/or obesity, the coexistence of these conditions contributes to a worse prognosis because both conditions confer an impaired immunologic system. Cytokines storm can be amplified by these two latter conditions thereby leading to multisystemic failure and death. Glycaemic control has been demonstrated to be crucial to avoiding long hospital stays, ICU requirement and also prevention of excessive mortality. Endocrine treatment modifications as a consequence of COVID-19 infection are required in a proactive manner, in order to avoid decompensation and eventual hospital admission. This is the case of diabetes and adrenal insufficiency in which prompt increase of insulin dosage and substitutive adrenal steroids through adoption of the sick day's rules should be warranted, as well as easy contact with the health care provider through telematic different modalities. New possible endocrinological targets of COVID-19 have been recently described and warrant a full study in the next future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.